AR076028A1 - REPLACED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS OF THE SAME, AND METHODS FOR USE - Google Patents
REPLACED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS OF THE SAME, AND METHODS FOR USEInfo
- Publication number
- AR076028A1 AR076028A1 ARP100101078A ARP100101078A AR076028A1 AR 076028 A1 AR076028 A1 AR 076028A1 AR P100101078 A ARP100101078 A AR P100101078A AR P100101078 A ARP100101078 A AR P100101078A AR 076028 A1 AR076028 A1 AR 076028A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- optionally
- alkyl
- heteroaryl
- heterocyclic
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 18
- 125000001072 heteroaryl group Chemical group 0.000 abstract 15
- 125000000623 heterocyclic group Chemical group 0.000 abstract 15
- 229910052739 hydrogen Inorganic materials 0.000 abstract 15
- 150000002431 hydrogen Chemical group 0.000 abstract 15
- 239000001257 hydrogen Substances 0.000 abstract 15
- 125000002723 alicyclic group Chemical group 0.000 abstract 14
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 125000003118 aryl group Chemical group 0.000 abstract 13
- 125000005343 heterocyclic alkyl group Chemical group 0.000 abstract 10
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 9
- 125000005842 heteroatom Chemical group 0.000 abstract 9
- 229910052760 oxygen Inorganic materials 0.000 abstract 9
- 229910052717 sulfur Inorganic materials 0.000 abstract 9
- 125000003342 alkenyl group Chemical group 0.000 abstract 8
- 125000000304 alkynyl group Chemical group 0.000 abstract 8
- 125000002947 alkylene group Chemical group 0.000 abstract 7
- -1 alicyclicalkyl Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052805 deuterium Inorganic materials 0.000 abstract 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan ciertos inhibidores de Hsp90, esto es, compuestos de la formula 1 y sales farmacéuticamente aceptables del mismo, composiciones farmacéuticas de los mismos, y método para su uso y preparacion. Reivindicacion 1: Un compuesto representado por la formula (1) o una sal farmacéuticamente aceptable del mismo, caracterizado porque X es un enlace o una cadena alquileno de la formula (CRaRb)n donde n es 1 hasta 3, para cada que se presenta, Ra y Rb se seleccionan independientemente de hidrogeno, alquilo, alicíclico, heterocíclico, arilo, y heteroarilo, cada uno de los cuales, excepto para hidrogeno, se substituye opcionalmente, y una unidad (CRaRb) se reemplaza opcionalmente por -O-, -N(Ra)-, o -S-; o cuando n es 2 o 3, Ra en una primera unidad (CRaRb) se toma opcionalmente junto con Ra en una unidad diferente (CRaRb) para formar un anillo opcionalmente substituido de 3-8 átomos del anillo en donde opcionalmente uno o dos de los 3-8 átomos del anillo son heteroátomos seleccionados independientemente de O, S, =N, y NR90; o Ra se toma opcionalmente junto con Rb en la misma O, S, =N, y NR90; o cuando X es una cadena de alquileno opcionalmente substituido de la formula (CRaRb), n es 1, y la unidad (CRaRb) se reemplaza por -N(Ra)-, entonces R3 y R4 tomados juntos opcionalmente forman oxo; o cuando X es una cadena de alquileno opcionalmente substituido de la formula (CRaRb)n, una unidad Ra se toma opcionalmente junto con R1 para formar un anillo opcionalmente substituido de 3-8 átomos del anillo en donde opcionalmente uno o dos de los 3-8 átomos del anillo son heteroátomos seleccionados independientemente de O, S, =N, y NR90; o cuando X es una cadena de alquileno opcionalmente substituido de la formula (CRaRb), un Ra en una primera unidad (CRaRb) se toma opcionalmente junto con R3 para formar un anillo opcionalmente substituido de 3-8 átomos del anillo en donde opcionalmente uno o dos de los 3-8 átomos del anillo son heteroátomos seleccionados independientemente de O, S, =N, y NR90; o cuando X es un enlace, R1 se toma opcionalmente junto con R3 para formar un anillo opcionalmente substituido de 3-8 átomos del anillo en donde opcionalmente uno o dos de los 3-8 átomos del anillo son heteroátomos seleccionados independientemente de O, S, =N, y NR90; R5 y R6 se seleccionan independientemente de hidrogeno, alquilo, alicíclico, heterocíclico, arilo y heteroarilo, cada uno de los cuales, excepto para unidad (CRaRb) para formar un anillo opcionalmente substituido de 3-8 átomos del anillo en donde opcionalmente uno o dos de los 3-8 átomos del anillo son heteroátomos seleccionados independientemente de O, S, =N, y NR90; R1 se selecciona de hidrogeno, halogeno, -OR11, -SR12, amino, y alquilo inferior opcionalmente substituido; o R2 se selecciona de -NR21R22, -N=C-NR21R22, -NR21-C(O)R23 y -NR21-SO2R24; R3 y R4 se seleccionan independientemente de hidrogeno, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente substituido, alicíclico opcionalmente substituido, alicíclicoalquilo opcionalmente substituido, heterocíclico opcionalmente sustituido, heterocíclicoalquilo opcionalmente substituido, arilo opcionalmente substituido, arilalquilo opcionalmente substituido, heteroarilo opcionalmente substituido, heteroarilalquilo opcionalmente substituido, -C(=J)Rx, -C(=J)N(Ry)(Rz), C(=J)N(Rx)S(O)2Rx, -C(=J)N(Rx)N(Rx)S(O)2Rx, -C(Rx) =N(ORx), -C(Rx) =NN(Ry)(Rz), -C:::N, -C(=J)ORx, -C(=J)SRx, -N(Ry)(Rz), -N(Rx)C(=J)Rx, -N(Rx)C(=J)N(Ry)(Rz), -N(Rx)C(=J)ORx, -N(Rx)C(=J)SRx, -N(Rx)S(O)2Rw, -N(Rx)S(O)2ORx, -S(O)tORx (donde t es 1 o 2), -S(O)NRyRz, -NH-C(-NH2)=C-NO2, -CO-NH-SO2-NH2, -N(Rx)S(O)2N(Ry)(Rz), N3, NO2, -ORx, -OC(=J)Rx, -OC(=J)ORx, -OC(=J)N(Ry)(Rz), -OC(=J)SRx, -OP(O)(Rv)2, -OS(O)2Rx, -OS(O)2N(Ry)(Rz), -OSi(Rw)3, -P(O)(Rv)2, -SRx, -S(O)tRx (donde t es 1 o 2), -S(O)2N(Ry)(Rz), -Si(Rw)3, y halogeno, en donde cada uno de J es independientemente O, NRu o S en donde cada uno de Ru es independientemente hidrogeno, alquilo, alquenilo, alquinilo, ciano, alicíclico, alicíclicoalquilo, heterocíclico, heterocíclicoalquilo, arilo, arilalquilo, heteroarilo, o heteroarilalquilo; cada uno de Rv es independientemente alquilo, alquenilo, alquinilo, alicíclico, alicíclicoalquilo, heterocíclico, heterocíclicoalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, hidroxi, -ORx o -N(Ry)(Rz); cada uno de Rw es independientemente alquilo, alquenilo, alquinilo, alicíclico, alicíclicoalquilo, heterocíclico, heterocíclicoalquilo, arilo, arilalquilo, heteroarilo, o heteroarilalquilo; cada uno de Rx es independientemente hidrogeno, alquilo, alquenilo, alquinilo, alicíclico, alicíclicoalquilo, heterocíclico, heterocíclicoalquilo, arilo, arilalquilo, heteroarilo, o heteroarilalquilo; y Ry y Rz son cada uno independientemente hidrogeno, alquilo, alquenilo, alquinilo, alicíclico, alicíclicoalquilo, heterocíclico, heterocíclicoalquilo, arilo, arilalquilo, heteroarilo, o heteroarilalquilo; o Ry y Rz, junto con el átomo de nitrogeno al cual se enlazan, forman un heterocíclico o heteroarilo; o R3 se toma opcionalmente junto con R4 para formar un anillo opcionalmente substituido de 3-8 átomos del anillo en donde opcionalmente uno o dos de los 3-8 átomos del anillo son heteroátomos seleccionados independientemente de hidrogeno, se substituye opcionalmente; o R5 se toma opcionalmente junto con R6, para formar un anillo opcionalmente substituido de 3-8 átomos del anillo en donde opcionalmente uno o dos de los 3-8 átomos del anillo son heteroátomos seleccionados independientemente de O, S, =N, y NR90; o cuando X es una cadena de alquileno opcionalmente substituido de la formula (CRaRb) , n es 1, y la unidad (CRaRb) se reemplaza por -N(Ra)-, entonces R5 y R6 tomados juntos opcionalmente forman oxo; o R3 se toma opcionalmente junto con R5, para formar un anillo opcionalmente substituido de 3-8 átomos del anillo en donde opcionalmente uno o dos de los 3-8 átomos del anillo son heteroátomos seleccionados independientemente de O, S, =N, y NR90; R7 se selecciona de un enlace, opcionalmente substituido alquileno, -C(O)-, -C(S)-, -S(O)-, y -SO2-; R8 se selecciona de alquilo, alicíclico, heterocíclico, arilo, y heteroarilo, cada uno de los cuales se substituye opcionalmente; R11 y R12 se seleccionan independientemente de hidrogeno, alquilo, alicíclico, heterocíclico, arilo y heteroarilo, cada uno de los cuales, excepto para hidrogeno, se substituye opcionalmente; y R21 y R22 se seleccionan independientemente de hidrogeno, alquilo, alicíclico, alicíclicoalquilo, heterocíclico, heterocíclicoalquilo, arilo, arilalquilo, heteroarilo, y heteroarilalquilo, cada uno de los cuales, excepto para hidrogeno, se substituye opcionalmente, o R21 se toma opcionalmente junto con R22 para formar un anillo opcionalmente substituido de 3-8 átomos del anillo en donde el anillo opcionalmente substituido opcionalmente incluye uno o dos átomos del anillo adicionales que son heteroátomos seleccionados independientemente de O, S, =N, y NR90; R23 se selecciona de hidrogeno, alquilo, alquenilo, alquinilo, alicíclico, alicíclicoalquilo, heterocíclico, heterocíclicoalquilo, arilo, arilalquilo, heteroarilo, y heteroarilalquilo; R24 se selecciona de alquilo, alquenilo, alquinilo, alicíclico, alicíclicoalquilo, heterocíclico, heterocíclicoalquilo, arilo, arilalquilo, heteroarilo, y heteroarilalquilo; y R90 se selecciona de hidrogeno, alquilo, alquenilo, alquinilo, alicíclico, alicíclicoalquilo, heterocíclico, heterocíclicoalquilo, arilo, arilalquilo, heteroarilo, y heteroarilalquilo; y en donde desde 1 hasta 5 átomos de hidrogeno en el compuesto de la formula (1) se reemplazan opcionalmente con deuterio, y con la condicion de que cuando X es una cadena de alquileno opcionalmente substituido de la formula (CRaRb)n, n es 1, la unidad (CRaRb) se reemplaza por -N(Ra)-, y R7 es -CH2- entonces R8 no es 3,5-dimetil-4-metoxi-piridin-2-il.Certain Hsp90 inhibitors are provided, that is, compounds of formula 1 and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and method for use and preparation. Claim 1: A compound represented by the formula (1) or a pharmaceutically acceptable salt thereof, characterized in that X is a bond or an alkylene chain of the formula (CRaRb) n where n is 1 to 3, for each which is presented, Ra and Rb are independently selected from hydrogen, alkyl, alicyclic, heterocyclic, aryl, and heteroaryl, each of which, except for hydrogen, is optionally substituted, and a unit (CRaRb) is optionally replaced by -O-, -N (Ra) -, or -S-; or when n is 2 or 3, Ra in a first unit (CRaRb) is optionally taken together with Ra in a different unit (CRaRb) to form an optionally substituted ring of 3-8 ring atoms where optionally one or two of the 3-8 ring atoms are heteroatoms independently selected from O, S, = N, and NR90; or Ra is optionally taken together with Rb in the same O, S, = N, and NR90; or when X is an optionally substituted alkylene chain of the formula (CRaRb), n is 1, and the unit (CRaRb) is replaced by -N (Ra) -, then R3 and R4 taken together optionally form oxo; or when X is an optionally substituted alkylene chain of the formula (CRaRb) n, a unit Ra is optionally taken together with R1 to form an optionally substituted ring of 3-8 ring atoms where optionally one or two of the 3- 8 ring atoms are heteroatoms independently selected from O, S, = N, and NR90; or when X is an optionally substituted alkylene chain of the formula (CRaRb), a Ra in a first unit (CRaRb) is optionally taken together with R3 to form an optionally substituted ring of 3-8 ring atoms where optionally one or two of the 3-8 ring atoms are heteroatoms independently selected from O, S, = N, and NR90; or when X is a bond, R1 is optionally taken together with R3 to form an optionally substituted ring of 3-8 ring atoms where optionally one or two of the 3-8 ring atoms are heteroatoms independently selected from O, S, = N, and NR90; R5 and R6 are independently selected from hydrogen, alkyl, alicyclic, heterocyclic, aryl and heteroaryl, each of which, except for unit (CRaRb) to form an optionally substituted ring of 3-8 ring atoms where optionally one or two of the 3-8 ring atoms are heteroatoms independently selected from O, S, = N, and NR90; R1 is selected from hydrogen, halogen, -OR11, -SR12, amino, and optionally substituted lower alkyl; or R2 is selected from -NR21R22, -N = C-NR21R22, -NR21-C (O) R23 and -NR21-SO2R24; R3 and R4 are independently selected from hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alicyclic, optionally substituted alicyclic alkyl, optionally substituted heterocyclic, optionally substituted heterocyclic alkyl, optionally substituted aryl, optionally substituted heteroaryl, heteroaryl substituted alkyl optionally substituted, -C (= J) Rx, -C (= J) N (Ry) (Rz), C (= J) N (Rx) S (O) 2Rx, -C (= J) N (Rx) N (Rx) S (O) 2Rx, -C (Rx) = N (ORx), -C (Rx) = NN (Ry) (Rz), -C ::: N, -C (= J) ORx, -C (= J) SRx, -N (Ry) (Rz), -N (Rx) C (= J) Rx, -N (Rx) C (= J) N (Ry) (Rz), -N ( Rx) C (= J) ORx, -N (Rx) C (= J) SRx, -N (Rx) S (O) 2Rw, -N (Rx) S (O) 2ORx, -S (O) tORx ( where t is 1 or 2), -S (O) NRyRz, -NH-C (-NH2) = C-NO2, -CO-NH-SO2-NH2, -N (Rx) S (O) 2N (Ry) (Rz), N3, NO2, -ORx, -OC (= J) Rx, -OC (= J) ORx, -OC (= J) N (Ry) (Rz), -OC (= J) SRx, - OP (O) (Rv) 2, -OS (O) 2Rx, -OS (O) 2N (Ry) (Rz), -OSi (Rw) 3, -P (O) (Rv) 2, -SRx, - S (O) tRx (where do you s 1 or 2), -S (O) 2N (Ry) (Rz), -Si (Rw) 3, and halogen, where each of J is independently O, NRu or S where each of Ru is independently hydrogen, alkyl, alkenyl, alkynyl, cyano, alicyclic, alicyclicalkyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; each of Rv is independently alkyl, alkenyl, alkynyl, alicyclic, alicyclicalkyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, hydroxy, -ORx or -N (Ry) (Rz); each of Rw is independently alkyl, alkenyl, alkynyl, alicyclic, alicyclicalkyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; each of Rx is independently hydrogen, alkyl, alkenyl, alkynyl, alicyclic, alicyclicalkyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; and Ry and Rz are each independently hydrogen, alkyl, alkenyl, alkynyl, alicyclic, alicyclicalkyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl; or Ry and Rz, together with the nitrogen atom to which they bind, form a heterocyclic or heteroaryl; or R3 is optionally taken together with R4 to form an optionally substituted ring of 3-8 ring atoms wherein optionally one or two of the 3-8 ring atoms are heteroatoms independently selected from hydrogen, optionally substituted; or R5 is optionally taken together with R6, to form an optionally substituted ring of 3-8 ring atoms where optionally one or two of the 3-8 ring atoms are heteroatoms independently selected from O, S, = N, and NR90 ; or when X is an optionally substituted alkylene chain of the formula (CRaRb), n is 1, and the unit (CRaRb) is replaced by -N (Ra) -, then R5 and R6 taken together optionally form oxo; or R3 is optionally taken together with R5, to form an optionally substituted ring of 3-8 ring atoms where optionally one or two of the 3-8 ring atoms are heteroatoms independently selected from O, S, = N, and NR90 ; R7 is selected from a bond, optionally substituted alkylene, -C (O) -, -C (S) -, -S (O) -, and -SO2-; R8 is selected from alkyl, alicyclic, heterocyclic, aryl, and heteroaryl, each of which is optionally substituted; R11 and R12 are independently selected from hydrogen, alkyl, alicyclic, heterocyclic, aryl and heteroaryl, each of which, except for hydrogen, is optionally substituted; and R21 and R22 are independently selected from hydrogen, alkyl, alicyclic, alicyclicalkyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each of which, except for hydrogen, is optionally substituted, or R21 is optionally taken together with R22 to form an optionally substituted ring of 3-8 ring atoms wherein the optionally substituted ring optionally includes one or two additional ring atoms that are heteroatoms independently selected from O, S, = N, and NR90; R23 is selected from hydrogen, alkyl, alkenyl, alkynyl, alicyclic, alicyclicalkyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; R24 is selected from alkyl, alkenyl, alkynyl, alicyclic, alicyclicalkyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and R90 is selected from hydrogen, alkyl, alkenyl, alkynyl, alicyclic, alicyclicalkyl, heterocyclic, heterocyclicalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and wherein from 1 to 5 hydrogen atoms in the compound of the formula (1) are optionally replaced with deuterium, and with the proviso that when X is an optionally substituted alkylene chain of the formula (CRaRb) n, n is 1, the unit (CRaRb) is replaced by -N (Ra) -, and R7 is -CH2- then R8 is not 3,5-dimethyl-4-methoxy-pyridin-2-yl.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16545309P | 2009-03-31 | 2009-03-31 | |
| US16545709P | 2009-03-31 | 2009-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076028A1 true AR076028A1 (en) | 2011-05-11 |
Family
ID=42936474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101078A AR076028A1 (en) | 2009-03-31 | 2010-03-31 | REPLACED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS OF THE SAME, AND METHODS FOR USE |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR076028A1 (en) |
| TW (1) | TW201102391A (en) |
| WO (1) | WO2010117425A1 (en) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER |
| UA112517C2 (en) | 2010-07-06 | 2016-09-26 | Новартіс Аг | TETRAHYDROPYRIDOPYRIMIDINE DERIVATIVES |
| AU2011326071A1 (en) | 2010-11-08 | 2013-05-23 | Lycera Corporation | N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| KR102063098B1 (en) * | 2011-10-03 | 2020-01-08 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | Pyrrolopyrimidine compounds for the treatment of cancer |
| DK2794600T3 (en) | 2011-12-22 | 2018-03-12 | Novartis Ag | -2,3-Dihydro-benzo [1,4] oxazine derivatives and related compounds such as phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of rheumatoid arthritis |
| CN104254533B (en) * | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | The pyridinyl compounds of thiazole or thiadiazoles substitution as kinase inhibitor |
| MX367341B (en) | 2012-05-08 | 2019-08-14 | Merck Sharp & Dohme | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE. |
| US9394315B2 (en) | 2012-05-08 | 2016-07-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| CN104302627A (en) | 2012-05-22 | 2015-01-21 | 北卡罗来纳大学教堂山分校 | Pyrimidine compounds for the treatment of cancer |
| BR112014029301A2 (en) | 2012-05-25 | 2017-07-25 | Berg Llc | Methods of treating metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
| ES2984771T3 (en) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Substituted tricyclic compounds as FGFR inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE-BASED COMPOUNDS FOR USE IN THE TREATMENT OF CANCER |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| EA035095B1 (en) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Bicyclic heterocycles as fgfr inhibitors |
| WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2015109109A1 (en) * | 2014-01-15 | 2015-07-23 | Forum Pharmaceuticals Inc. | Fused morpholinopyrimidines and methods of use thereof |
| CA2939305A1 (en) | 2014-02-27 | 2015-09-03 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods |
| SG11201607586UA (en) | 2014-03-13 | 2016-10-28 | Agency Science Tech & Res | Fused pyrimidine-based hydroxamate derivatives |
| WO2015157123A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrrolopyrimidine compounds |
| CA2947290A1 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| WO2015171558A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
| AU2015257917C1 (en) | 2014-05-07 | 2019-03-14 | Evotec International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
| AU2015269054A1 (en) | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EA038045B1 (en) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| JP2018515491A (en) | 2015-05-05 | 2018-06-14 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | Dihydro-2H-benzo [b] [1,4] oxazinesulfonamide and related compounds for use as RORγ agonists and disease therapies |
| EP3307738B1 (en) | 2015-06-11 | 2022-04-20 | The Regents of the University of Michigan | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| CA3002846A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof |
| WO2017075182A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
| WO2017075185A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| CN107827871B (en) * | 2017-11-03 | 2019-12-06 | 梯尔希（南京）药物研发有限公司 | preparation method of omeprazole metabolite |
| RS66310B1 (en) | 2018-05-04 | 2025-01-31 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| CN110872297B (en) * | 2018-09-04 | 2023-02-14 | 上海再极医药科技有限公司 | Aminopyrimidine five-membered heterocyclic compound, intermediate thereof, preparation method, pharmaceutical composition and application |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2024513575A (en) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Combination therapy including FGFR inhibitor and Nectin-4 targeting agent |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (en) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | Tricyclic heterocycles as fgfr inhibitors |
| WO2024199473A1 (en) * | 2023-03-31 | 2024-10-03 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138402B2 (en) * | 2003-09-18 | 2006-11-21 | Conforma Therapeutics Corporation | Pyrrolopyrimidines and related analogs as HSP90-inhibitors |
-
2010
- 2010-03-30 TW TW099109701A patent/TW201102391A/en unknown
- 2010-03-30 WO PCT/US2010/000958 patent/WO2010117425A1/en not_active Ceased
- 2010-03-31 AR ARP100101078A patent/AR076028A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010117425A1 (en) | 2010-10-14 |
| TW201102391A (en) | 2011-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076028A1 (en) | REPLACED PYRIMIDINS, PHARMACEUTICAL COMPOSITIONS OF THE SAME, AND METHODS FOR USE | |
| AR077695A1 (en) | PIRIMIDINE DERIVATIVES AS INHIBITORS OF FACTOR IXA | |
| DOP2011000061A (en) | PIRROL COMPOUNDS | |
| ES2669189T3 (en) | Carbazole compounds useful as bromodomain inhibitors | |
| ES2600636T3 (en) | Spiro- [1,3] -oxazines and spiro- [1,4] -oxazepines as inhibitors of BACE1 and / or BACE2 | |
| ES2586527T3 (en) | Heterocyclic compounds and use thereof as type III tyrosine kinase receptor modulators | |
| AR082029A1 (en) | DERIVATIVES OF NITROGEN HETEROCICLES, COMPOSITIONS AND METHODS TO MODULATE THE WNT SIGNALING ROAD | |
| AR077292A1 (en) | DERIVATIVES OF PIPERAZIN - QUINOLIN SULFONAMIDS AND PHARMACEUTICAL COMPOSITIONS | |
| ES2524398T3 (en) | Methods for the preparation of diastereomerically pure phosphoramidate prodrugs | |
| PE20140863A1 (en) | BENZENE COMPOUNDS REPLACED WITH ARYL OR HETEROARYL | |
| AR063601A1 (en) | ARILAMIDAS REPLACED BY TIAZOL OR OXAZOL | |
| AR082499A1 (en) | USEFUL COMPOUNDS FOR NERVOUS SYSTEM, INFLAMMATORY, STOMACH AND AS ANALGESIC DISORDERS | |
| ES2422204T3 (en) | Novel derivatives of imidazolidin-2-one as selective androgen receptor modulators (SARMS) | |
| AR093184A1 (en) | PIRIMIDINE COMPOSITE REPLACED AS AN INHIBITOR OF QUINURENINA-3-MONOOXIGENASA AND PHARMACEUTICAL COMPOSITION THAT UNDERSTAND IT | |
| AR076170A1 (en) | HIDEROCICLIC IMIDAZOLIC AND / OR OXAZOLIC DERIVATIVES USED AS ANTIVIRAL AGENTS FOR HEPATITIS C AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM | |
| AR085615A1 (en) | USEFUL FLUOROPIRIDINONE DERIVATIVES AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| DOP2011000281A (en) | BENZOFURAN DERIVATIVES | |
| AR082886A1 (en) | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| MX337714B (en) | Hetero ring-fused imidazole derivative having ampk activating effect. | |
| AR089182A1 (en) | AMINOPIRIMIDINE DERIVATIVES AS MODULATORS OF LRRK2 | |
| CO6801736A2 (en) | Heterocyclic Amine Derivatives | |
| ES2626801T3 (en) | Triazolopyridine compounds as pde10a inhibitors | |
| AR076008A1 (en) | DERIVATIVES OF HYDROXIMETHYL-ISOXAZOL GABA A RECEPTOR MODULATORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, METHOD FOR PREPARING THEM AND USE OF THE SAME FOR THE TREATMENT OF ALZHEIMER AND OTHER COGNITIVE DISORDERS. | |
| AR072803A1 (en) | TETRAHYDROCINOLINS AS INHIBITORS OF THE 11- BETA -HSD1 FOR DIABETES | |
| EA201391797A1 (en) | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |